Tafluprost

Tafluprost (CAS No.: 209860-87-7) is a synthetic prostaglandin F2 alpha analog that is broadly classified as a small molecule lipid mediator tool compound for ophthalmic and receptor pharmacology research, and it is primarily used to investigate prostanoid signaling biology in preclinical experimental systems relevant to biomedical discovery workflows. Mechanistically, available evidence indicates that tafluprost functions as an agonist of the prostaglandin F receptor axis, with downstream engagement of G protein coupled signaling networks that can modulate phospholipase C linked cascades, intracellular calcium dynamics, and tissue level responses associated with extracellular matrix remodeling and fluid homeostasis, thereby supporting its value as a probe for pathway interrogation rather than non research use. In vitro pharmacology reported for prostaglandin F receptor active analogs, including tafluprost in receptor focused assays, is generally described within nanomolar to low micromolar concentration ranges depending on assay format, receptor expression context, and endpoint selection, and researchers typically confirm concentration response relationships across orthogonal readouts to distinguish primary receptor driven effects from secondary cellular adaptations. In practice, this compound is commonly incorporated into cell based mechanistic studies, target validation workflows, and comparative profiling against other prostanoid ligands, while in vivo use in animal models is generally designed to evaluate pathway dependent physiological phenotypes under controlled laboratory conditions, and the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.